Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China
- Chinese National Medical Products Administration (NMPA) granted Drug Approval License for Cresemba in China to Basilea’s license partner Pfizer
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, December 21, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced today that its license partner, Pfizer Inc. (NYSE: PFE, “Pfizer”), has received a Drug Approval License from the National Medical Products Administration (NMPA) in China, for the oral formulation of its antifungal Cresemba® (isavuconazole). With this authorization, oral Cresemba is now approved in China for the treatment of adult patients with invasive mucormycosis. The granting of the Drug Approval License triggered a milestone payment of USD 10 million from Pfizer to Basilea. The intravenous formulation for the treatment of invasive mucormycosis is currently being reviewed under a separate marketing authorization application.
In October 2020, Pfizer also submitted marketing authorization applications for oral and intravenous Cresemba for the treatment of invasive aspergillosis. These applications are under regulatory review by the Center for Drug Evaluation at the NMPA.
David Veitch, Basilea’s CEO said: “We congratulate our partner Pfizer on the approval of Cresemba for the treatment of adult patients with invasive mucormycosis in China. Invasive fungal infections, such as mucormycosis, can pose a serious threat to patients if left untreated. With this approval, patients in China who are suffering from mucormycosis will now have access to a treatment that can help to address their unmet needs. China is a very important commercial market for Cresemba, accounting for approximately 20 percent of global sales for newer antifungals.”
The license agreement between Basilea and Pfizer covers Europe (excluding the Nordic countries), Russia, Turkey and Israel, as well as China (including Hong Kong and Macao) and sixteen countries in the Asia Pacific region. In addition to receiving mid-teen royalties on sales, Basilea remains eligible for further milestone payments of up to approximately USD 600 million under the agreement with Pfizer.
Cresemba has been approved in more than 60 countries to date and is currently marketed in 55 countries, including the United States, most EU member states and additional countries inside and outside of Europe. In the twelve-month period between July 2020 and June 2021, total "in-market" sales of Cresemba amounted to USD 285 million, a 24 percent growth year-on-year.1
About invasive aspergillosis and invasive mucormycosis
Invasive aspergillosis and invasive mucormycosis are life-threatening mold infections that predominantly affect immunocompromised patients, such as patients with hematologic malignancies (blood cancer). Both infections are associated with high morbidity and mortality.
About isavuconazole (Cresemba)
Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.2 In China, the oral formulation is approved for the treatment of adult patients with invasive mucormycosis. Isavuconazole is also approved in the United States and several additional countries in Europe and beyond.3 It has orphan drug designation in the U.S., Europe and Australia for its approved indications.
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
|Phone||+41 61 606 1102|
This ad hoc announcement can be downloaded from www.basilea.com.
- IQVIA, June 2021. In-market sales reported as moving annual total (MAT) in U.S. dollar.
- European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: December 20, 2021]
- The registration status and approved indications may vary from country to country.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Aspo Group half-year financial report, January 1 to June 30, 2022: Strong performance continued in Q2; Comparable operating profit reached a record-high EUR 16.0 million10.8.2022 08:30:00 CEST | Press release
Aspo Plc Half-year financial report August 10, 2022, at 9:30 am Aspo Group half-year financial report, January 1 to June 30, 2022 Strong performance continued in Q2: Comparable operating profit reached a record-high EUR 16.0 million Figures from the corresponding period in 2021 are presented in brackets. April–June 2022, continuing operations Aspo’s net sales increased by 16% to EUR 161.4 (139.3) million.Comparable operating profit, at Group total level was EUR 16.0 (9.6) million, and the comparable operating profit rate was 9.7% (6.7%).The comparable operating profit of ESL Shipping was EUR 9.2 (5.4) million, Telko EUR 7.2 (5.5) million, and Leipurin EUR 0.9 (0.3) million.Items affecting the comparability of operating profit totaled EUR -2.4 million at Group total level.Operating profit was EUR 14.8 (9.6) million. The operating profit rate was 9.2% (6.9%).The operating profit of ESL Shipping was EUR 9.0 (5.4) million, Telko EUR 6.8 (5.5) million, and Leipurin EUR 0.4 (0.3) million.Ear
UPDATE ON MBCC ACQUISITION – CLOSING TARGETED FOR H1 202310.8.2022 08:00:00 CEST | Press release
UPDATE ON MBCC ACQUISITION – CLOSING TARGETED FOR H1 2023 The UK Competition and Markets Authority (CMA) has decided to conduct an in-depth examination in the UK market related to Sika’s planned acquisition of MBCC Group. Closing is now targeted for the first half of 2023. The adapted timeline will not impact the strategic attractiveness of the transaction. Guidance for the expected annual synergies remains at CHF 160 – 180 million. In November 2021, Sika signed a definitive agreement to acquire MBCC Group (former BASF Construction Chemicals). The completion of the transaction is subject to regulatory approvals. The UK Competition and Markets Authority (CMA) has decided to conduct an in-depth examination (Phase 2) regarding Sika’s planned acquisition of MBCC Group. This examination will require additional time. The closing of the transaction is therefore now targeted for the first half of 2023 instead of at the end of 2022 as previously announced. Thomas Hasler, Chief Executive Officer
Ahold Delhaize delivers resilient performance in Q2 2022; raises full-year EPS and free cash flow guidance10.8.2022 07:45:00 CEST | Press release
With high levels of inflation, our brands are focused on helping customers efficiently manage their spending. Driven by our €850 million Save For Our Customers cost savings program, our brands are absorbing cost increases for customers, introducing more entry-priced products, expanding high-quality own-brand assortments and delivering personalized value through loyalty programs.Q2 Group net sales increased 6.4% at constant exchange rates to €21.4 billion. At actual exchange rates, net sales grew 15.0%. Q2 net sales accelerated in both regions compared to Q1, growing 7.7% in the U.S. and 4.2% in Europe at constant rates. Increased market share in the majority of markets reflects strong customer loyalty to our locally tailored customer value propositions.Net consumer online sales increased 4.8% at constant exchange rates. Net consumer online sales in grocery increased 11.5% at constant exchange rates, as we continue to invest in creating the leading local omnichannel food experience.Q2 u
Ageas reports first half-year results 202210.8.2022 07:30:00 CEST | Press release
Ageasreportsfirst half-yearresults 2022 The strong commercial start continued across the businessExcelling on all operating targetsInterim dividend of EUR 1.5 per share KeyFiguresResultGroupnetresult excluding RPN(i) amounted to EUR456millionInflowsGroup inflows were up 5% to EUR 9 billion with increases in both Life and Non-LifeLife inflows increased by 5% to EUR 6.3 billion driven by Belgium and new business in ChinaNon-Life inflows were up 5% to EUR 2.7 billion mainly thanks to Belgium and PortugalOperatingPerformanceCombined ratio stood at 94.9%, including 5pp impact from adverse weather events in Belgium and the UK during the first quarterOperating Margin Guaranteed stood at 95 bps and Operating Margin Unit-Linked amounted to 39 bpsBalanceSheetShareholders’ equity amounted to EUR 9 billion or EUR 49.11 per shareGroup Solvency IIageas ratio improved to 221%, well within the Group’s risk appetiteThe Operational Capital Generation and the Operational Free Capital Generation respectiv
Sampo plc’s share buybacks 09/08/202210.8.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 10/08/2022 at 08:30 am Sampo plc’s share buybacks 09/08/2022 On 09/08/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)15,16644.84AQEU29,39144.85CEUX9,01844.87TQEX50,00344.82XHELTOTAL103,57844.84 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 5,818,340 Sampo A shares representing 1.09 per cent of the total number of shares in Sampo plc. Details of ea